Short answers
Questions the notebook gets most often.
Seven short answers, each lifted from a full note. Follow the link under an answer for the evidence and the sources.
What is the difference between a peptide and a protein?
Both are chains of amino acids joined by peptide bonds. The difference is mostly length and folded shape, and the boundary is a convention rather than a law of chemistry. Read where the line actually sits.
Why are most peptide medicines injected?
Stomach acid and enzymes such as pepsin and trypsin cut peptides into single amino acids and short fragments. A drug that must arrive intact has to get past that, so most are injected. Read why most peptides cannot be swallowed.
Do peptides show up on drug tests?
Workplace panels screen for drugs of abuse, not peptides. Anti-doping laboratories are different: they target peptides directly and also look for metabolites after the parent molecule has cleared. Read the drug test note.
Is there an established BPC-157 cycle?
No. No study of BPC-157 defines a cycle. Rodent experiments ran from single doses to 90 days, and the three human reports were not dose finding studies. Read the BPC-157 cycle evidence.
Does tesamorelin cause cancer?
No study has shown that it does, but its one-year trials were not built to rule it out over the long term. The Egrifta label addresses neoplasms and IGF-1. Read the tesamorelin safety note.
What does "research use only" mean on a peptide?
It means the product has not been evaluated as a medicine and nobody has judged it fit for people. Pages that carry the phrase and also explain self-use contradict themselves. Read five red flags on a sales page.
Does Peptide House give dosing advice?
No. Notes record the amounts studies used and the doses approved labels print, so readers can check a claim against the record. Unapproved compounds have no established human dose, and no seller is ever named. See the editorial policy.
Last updated